<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724838</url>
  </required_header>
  <id_info>
    <org_study_id>aswu 193/7/18</org_study_id>
    <nct_id>NCT03724838</nct_id>
  </id_info>
  <brief_title>Esomeprazole With Sildenafil Citrate in Women With Early-onset Preeclampsia</brief_title>
  <official_title>Esomeprazole Alone or With Sildenafil Citrate in Women With Early-onset Preeclampsia: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown that expectant management of preeclampsia in the context of
      extreme prematurity may improve perinatal outcomes. Indeed, it has been estimated that for
      each additional day of pregnancy prolongation between 24 and 32 weeks of gestation, there is
      a nonlinear corresponding gain of 1% in fetal survival. In this study, we evaluate the use of
      Esomeprazole alone or with Sildenafil Citrate for the treatment of singleton pregnancies
      complicated by preeclampsia. We hypothesized that the potential increase in uteroplacental
      and fetoplacental blood flow with the use of Esomeprazole alone or with Sildenafil Citrate
      may be associated with pregnancy prolongation (the primary study outcome) and improved
      maternal and perinatal outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The etiology and pathophysiology of preeclampsia have not been clearly established; impaired
      immunologic adaptation and genetic incompatibility seem to be involved in deficient
      trophoblastic implantation. Placental hypoxia and endothelial dysfunction may lead to
      preeclampsia through an exacerbated systemic inflammatory reaction. Increased placental
      expression and secretion of soluble fms-like tyrosine kinase 1 appear to play a central role
      in the pathogenesis of preeclampsia. The soluble fms-like tyrosine kinase 1 antagonizes the
      proangiogenic biologic activity of circulating vascular endothelial growth factor and
      placental growth factor, leading to a failure of nitric oxide signaling to smooth muscle The
      investigators will conduct a randomized, double-blind, placebo-controlled trial designed to
      evaluate the efficacy and safety of Esomeprazole alone or with Sildenafil Citrate in preterm
      pregnancies complicated by preeclampsia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>We will conduct a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Esomeprazole alone or with Sildenafil Citrate in preterm pregnancies complicated by preeclampsia.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>both participants and researchers will be blinded to the intervention given</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prolongation of gestation measured from the time of enrollment to the time of delivery.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Prolongation of gestation measured from the time of enrollment to the time of delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe morbidity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Severe morbidity including eclampsia, liver or renal failure, hemolysis, elevated liver enzymes and low platelets syndrome (HELLP), disseminated intravascular coagulation (DIC), stroke, and pulmonary edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>4 weeks</time_frame>
    <description>any side effects or adverse events related to the intervention, intervention stopped due to side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in serum level of sFlt-1 and endoglin before the start of treatment and at termination of pregnancy</measure>
    <time_frame>4 weeks</time_frame>
    <description>The change in serum level of sFlt-1 and endoglin before the start of treatment and at termination of pregnancy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Esomeprazole with Sildenafil Citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole alone plus placebo to Sildenafil Citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo to Esomeprazole plus placebo to Sildenafil Citrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole with Sildenafil Citrate</intervention_name>
    <description>Patients will take esomeprazole single dose of 40 mg orally once a day</description>
    <arm_group_label>Esomeprazole alone plus placebo to Sildenafil Citrate</arm_group_label>
    <arm_group_label>Esomeprazole with Sildenafil Citrate</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>Patients will take Sildenafil Citrate 40mg every 8 hours</description>
    <arm_group_label>Esomeprazole with Sildenafil Citrate</arm_group_label>
    <other_name>active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Esomeprazole</intervention_name>
    <description>Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day</description>
    <arm_group_label>placebo to Esomeprazole plus placebo to Sildenafil Citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Sildenafil Citrate</intervention_name>
    <description>Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours</description>
    <arm_group_label>Esomeprazole alone plus placebo to Sildenafil Citrate</arm_group_label>
    <arm_group_label>placebo to Esomeprazole plus placebo to Sildenafil Citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women presenting at a Gestational age between 28 + 0 weeks and 32 + 0 weeks
             presented with preterm preeclampsia

          -  The patient will be managed with an expectant management

          -  Give written informed consent

        Exclusion Criteria:

          -  Multiple pregnancies.

          -  Previous hypersensitivity reaction esomeprazole or sildenafil citrate

          -  Contraindications to the use of esomeprazole or sildenafil citrate

          -  The patient is unable or unwilling to give consent

          -  An established fetal compromise that necessitates delivery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women with early-onset preeclampsia</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f sallam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f sallam</last_name>
    <phone>01022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aswan University</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hany f sallam, md</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.ed.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla w Shady, m</last_name>
      <phone>1019240504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Esomeprazole</keyword>
  <keyword>Sildenafil Citrate</keyword>
  <keyword>preterm preeclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

